This is a theory so take from it what you will, but imo it has...

This is a theory so take from it what you will, but imo it has less to do with conspiracies and more to do with ordinary money making activities from institutional investors on a daily basis. Significant milestone coming up? Program the bot to raise the share a couple of dollars. News lands, short the shares down a couple of dollars. Repeat, repeat and repeat. Pretty standard fare for the ASX I reckon.

That said, I do believe some of the larger holders (ie a major bank nominees entity) like to keep a peg on the share price to react quickly when significantly positive news drops. But thats unremarkable in the scheme of things.

I'm concerned we will still be pegged at $20 post-Angelman results, however a successful FDA meeting will hopefully provide a roadmap to when the Phase 3 trial starts and give us an indication of how onerous the trial design will be. I'm expecting the design to be similar to the Phase 2 trial but with a greater sample number which will give confidence to the market the FDA is happy with how Neuren is progressing the drug. If the FDA also agree on a new trial protocol for PE and the undisclosed indications that could provide a timely boost also.